IMS 2022 | The long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated WM

Name: The long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated WM
Uploaded: 2022-08-25T00:00:00Z
Duration: 1 min 24 s
Description: Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term safety and efficacy of ibrutinib monotherapy in patients with previously treated Waldenström’s macroglobulinemia (WM), including those with MYD88 and CXCR4 mutations. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Steven Treon • 25 Aug 2022

IMS 2022

Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term safety and efficacy of ibrutinib monotherapy in patients with previously treated Waldenström’s macroglobulinemia (WM), including those with MYD88 and CXCR4 mutations. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.